309 related articles for article (PubMed ID: 27549509)
21. Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.
Halvorsen TO; Herje M; Levin N; Bremnes RM; Brustugun OT; Fløtten Ø; Kaasa S; Sundstrøm S; Grønberg BH
Lung Cancer; 2016 Dec; 102():9-14. PubMed ID: 27987595
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer.
Okamoto K; Okamoto I; Takeda M; Kobayashi S; Takeda K; Nakamatsu K; Nishimura Y; Nakagawa K
Jpn J Clin Oncol; 2014 Aug; 44(8):743-8. PubMed ID: 24868080
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
Killingberg KT; Halvorsen TO; Fløtten Ø; Brustugun OT; Langer SW; Nyman J; Hornslien K; Madebo T; Schytte T; Risum S; Tsakonas G; Engleson J; Grønberg BH
Lung Cancer; 2022 Apr; 166():49-57. PubMed ID: 35183991
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer.
Xia B; Hong LZ; Cai XW; Zhu ZF; Liu Q; Zhao KL; Fan M; Mao JF; Yang HJ; Wu KL; Fu XL
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):517-23. PubMed ID: 25481679
[TBL] [Abstract][Full Text] [Related]
25. Survival and prognostic factors in limited stage small cell lung cancer: A retrospective study from northeast Turkey.
Aynaci Ö; Canyilmaz E; Serdar L; Kandaz M; Bahat ZM; Yoney A
J Cancer Res Ther; 2016; 12(1):238-43. PubMed ID: 27072244
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
Misumi Y; Okamoto H; Sasaki J; Masuda N; Ishii M; Shimokawa T; Hosomi Y; Okuma Y; Nagamata M; Ogura T; Kato T; Sata M; Otani S; Takakura A; Minato K; Miura Y; Yokoyama T; Takata S; Naoki K; Watanabe K
BMC Cancer; 2017 May; 17(1):377. PubMed ID: 28549414
[TBL] [Abstract][Full Text] [Related]
27. Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004.
Hallqvist A; Rylander H; Björk-Eriksson T; Nyman J
Acta Oncol; 2007; 46(7):969-74. PubMed ID: 17851846
[TBL] [Abstract][Full Text] [Related]
28. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
[TBL] [Abstract][Full Text] [Related]
29. Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer: interim analysis of a prospective randomized noninferiority trial.
Hu X; Bao Y; Zhang L; Guo Y; Chen YY; Li KX; Wang WH; Liu Y; He H; Chen M
Cancer; 2012 Jan; 118(1):278-87. PubMed ID: 21598237
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
[TBL] [Abstract][Full Text] [Related]
31. Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
Shimada M; Yamaguchi H; Fukuda M; Tomono H; Honda N; Dotsu Y; Taniguchi H; Gyotoku H; Senju H; Takemoto S; Ikeda T; Nakatomi K; Nakamura Y; Nagashima S; Yamazaki T; Mukae H
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1059-1064. PubMed ID: 31486872
[TBL] [Abstract][Full Text] [Related]
32. Timing of thoracic radiotherapy in limited stage small cell lung cancer: results of early versus late irradiation from a single institution in Turkey.
Bayman E; Etiz D; Akcay M; Ak G
Asian Pac J Cancer Prev; 2014; 15(15):6263-7. PubMed ID: 25124609
[TBL] [Abstract][Full Text] [Related]
33. [Thoracic radiation therapy improves the prognosis for patients with extensive stage small-cell lung cancer].
Zhu H; Zhou ZM; Feng QF; Ou GF; Liang J; Zhang XR; Zhang HX; Chen DF; Xiao ZF; Wang LH
Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):142-6. PubMed ID: 21575486
[TBL] [Abstract][Full Text] [Related]
34. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
[TBL] [Abstract][Full Text] [Related]
35. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis.
Ludbrook JJ; Truong PT; MacNeil MV; Lesperance M; Webber A; Joe H; Martins H; Lim J
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1321-30. PubMed ID: 12654444
[TBL] [Abstract][Full Text] [Related]
36. Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer.
Morimoto M; Okishio K; Akira M; Omachi N; Tamiya A; Asami K; Kawaguchi T; Atagi S
Clin Lung Cancer; 2017 Mar; 18(2):e117-e127. PubMed ID: 28340925
[TBL] [Abstract][Full Text] [Related]
37. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
Salem A; Mistry H; Hatton M; Locke I; Monnet I; Blackhall F; Faivre-Finn C
JAMA Oncol; 2019 Mar; 5(3):e185335. PubMed ID: 30520977
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy.
Winther-Larsen A; Hoffmann L; Moeller DS; Khalil AA; Knap MM
Acta Oncol; 2015; 54(9):1574-81. PubMed ID: 26203924
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy on limited small cell lung cancer].
Hu X; Bao Y; Chen YY; Gao JM; Wang WH; Liu Y; He H; Sun ZW; Poudel S; Wang Y; Zhuang TT; Zhang L; Chen M
Ai Zheng; 2008 Oct; 27(10):1088-93. PubMed ID: 18851790
[TBL] [Abstract][Full Text] [Related]
40. Feasibility and efficacy of simultaneous integrated boost intensity-modulated radiation therapy in patients with limited-disease small cell lung cancer.
Han D; Qin Q; Hao S; Huang W; Wei Y; Zhang Z; Wang Z; Li B
Radiat Oncol; 2014 Dec; 9():280. PubMed ID: 25498196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
